SCHEMBL25238540

SCHEMBL25238540

CCn1nnc2ccc(N)c(OC)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 3/20 0.40
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
ALDH1A1 P00352 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
HCAR3 P49019 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KMT2A Q03164 2/20 0.31
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
GAA P10253 1/20 0.31
GRM2 Q14416 1/20 0.30
ACSS2 Q9NR19 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25285360 0.81 SLC9A1 (0.40) SLC9A1CLK1DYRK1ANPC1RAB9A
SCHEMBL25282764 0.79 HCAR3 (0.36) SLC9A1ALDH1A1NPC1RAB9AHCAR3
SCHEMBL25437723 0.72 ALDH1A1 (0.37) ALDH1A1NPC1RAB9AMAPTHPGD
SCHEMBL30498053 0.72 DPP4 (0.41) ALDH1A1NPC1RAB9AMAPTHSD17B10
SCHEMBL25754180 0.72 DPP4 (0.41) ALDH1A1NPC1RAB9AMAPTHSD17B10
SCHEMBL25271978 0.72 HTR2C (0.44) ALDH1A1NPC1RAB9AHPGDHSD17B10
SCHEMBL30498072 0.71 TDP1 (0.46) DYRK1AHSD17B10KMT2AACSS2
SCHEMBL27199552 0.71 TDP1 (0.46) DYRK1AHSD17B10KMT2AACSS2
SCHEMBL3653083 0.67 PIK3CD (0.33)
SCHEMBL25243568 0.65 TUBB4A (0.40) ALDH1A1MAPTTSHRHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 SLC9A1 4804/4885CLK1 606/4885DYRK1A 56/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 SLC9A1 4804/4885CLK1 606/4885DYRK1A 56/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 SLC9A1 4804/4885CLK1 606/4885DYRK1A 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.